Home
Clinical Trials
NCT00492258

Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer

Last Updated: 2013-08-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1656 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-06-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib after surgery may kill any tumor cells that remain after surgery. It is not yet known whether sorafenib is more effective than a placebo in treating kidney cancer.

PURPOSE: This randomized phase III trial is studying sorafenib to see how well it works compared with a placebo in treating patients at risk of relapse after undergoing surgery to remove kidney cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Compare disease-free survival of patients with resected primary renal cell carcinoma at high- or intermediate-risk of relapse treated with a placebo for 3 years vs a placebo for 2 years and sorafenib tosylate for 1 year vs sorafenib tosylate for 3 years.

OUTLINE: This is a randomized, placebo-controlled, double-blind, open-label, multicenter study. Patients are randomized to 1 of 3 treatment arms.

* Arm I: Patients receive oral placebo twice daily for 3 years in the absence of disease progression or unacceptable toxicity.
* Arm II: Patients receive oral sorafenib tosylate twice daily for 1 year and oral placebo twice daily for 2 years in the absence of disease progression or unacceptable toxicity.
* Arm III: Patients receive oral sorafenib tosylate twice daily for 3 years in the absence of disease progression or unacceptable toxicity.

Patients in arms I and II with progressive disease may cross over and receive treatment in arm III.

After completion of study treatment, patients are followed periodically.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

stage II renal cell cancer stage III renal cell cancer stage IV renal cell cancer stage I renal cell cancer clear cell renal cell carcinoma papillary renal cell carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sorafenib tosylate

Intervention Type DRUG

adjuvant therapy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed renal cell carcinoma (RCC)

* Clear cell or non-clear cell tumors allowed
* Intermediate- or high-risk disease (Leibovich score 3 to 11)
* Must have undergone surgery for RCC at least 4 weeks but no more than 3 months prior to study entry

* No evidence of residual macroscopic disease on post-operative CT scan after resection of RCC

PATIENT CHARACTERISTICS:

* WHO performance status 0-1
* WBC \> 3,400/mm³
* Platelet count \> 99,000/mm³
* Creatinine \< 2.5 times upper limit of normal (ULN)
* Liver function tests \< 1.5 times ULN
* Serum amylase \< 1.5 times ULN
* PT/INR \< 1.5 times ULN
* PTT \< 1.5 times ULN
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 9 months after completion of study treatment
* No cardiovascular conditions, including any of the following:

* Cardiac arrhythmias requiring anti-arrhythmic medication

* Beta-blockers and digoxin allowed
* Symptomatic coronary artery disease or ischemia
* Myocardial infarction within the past 6 months
* NYHA class II-IV congestive heart failure
* No active clinically serious bacterial or fungal infection
* No known history of HIV infection
* No chronic hepatitis B or C
* No other prior malignancy except carcinoma in situ of the cervix or adequately treated basal cell carcinoma
* No uncontrolled hypertension

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior treatment for RCC other than nephrectomy
* More than 30 days since prior and no other concurrent investigational therapy
* No concurrent medications that have adverse interactions with sorafenib tosylate including, but not limited to, any of the following:

* Rifampin
* Grapefruit juice
* Ritonavir
* Ketoconazole
* Itraconazole
* Hypericum perforatum (St John's wort)
* No concurrent bone marrow transplant or stem cell rescue
* No other concurrent drug that targets angiogenesis, especially VEGF or VEGF receptors (e.g., bevacizumab)
* No other concurrent drug that targets Ras-pathway or EGFR
* No other concurrent anticancer therapy (chemotherapy, immunotherapy, signal transduction inhibition, or hormonal therapy)
* Concurrent non-conventional therapies (e.g., herbs or acupuncture) and vitamin or mineral supplements allowed
* Concurrent bisphosphonates for prophylaxis of osteoporosis allowed

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Timothy Eisen

Role: PRINCIPAL_INVESTIGATOR

Cancer Research UK

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Royal Bournemouth Hospital

Bournemouth, England, United Kingdom

Site Status

Bristol Haematology and Oncology Centre

Bristol, England, United Kingdom

Site Status

Queen's Hospital

Burton-on-Trent, England, United Kingdom

Site Status

Addenbrooke's Hospital

Cambridge, England, United Kingdom

Site Status

Gloucestershire Oncology Centre at Cheltenham General Hospital

Cheltenham, England, United Kingdom

Site Status

Derbyshire Royal Infirmary

Derby, England, United Kingdom

Site Status

Dorset County Hospital

Dorchester, England, United Kingdom

Site Status

Gloucestershire Royal Hospital

Gloucester, England, United Kingdom

Site Status

Diana Princess of Wales Hospital

Grimsby, England, United Kingdom

Site Status

Princess Royal Hospital at Hull and East Yorkshire NHS Trust

Hull, England, United Kingdom

Site Status

Ipswich Hospital

Ipswich, England, United Kingdom

Site Status

Leeds Cancer Centre at St. James's University Hospital

Leeds, England, United Kingdom

Site Status

Leicester Royal Infirmary

Leicester, England, United Kingdom

Site Status